Low molecular weight heparin - Revision history

ClaireLewis: /* Background */

2019-09-19T17:28:25Z

Background

← Revisión anterior		Revisión del 17:28 19 sep 2019
Línea 1:		Línea 1:
	==Background==		==Background==
	*~~A class~~ of anticoagulant medications.		*Class of [[anticoagulant]] medications.
	*Defined as heparin salts having an average molecular weight of less than 8000 Dalton		*Defined as heparin salts having an average molecular weight of less than 8000 Dalton
	*LMWHs inhibit the coagulation process through binding to antithrombin which in turn inhibits activated factor X.<ref>Garcia DA, Baglin TP, Weitz JI, et al. (2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</ref>		*LMWHs inhibit the coagulation process through binding to antithrombin which in turn inhibits activated factor X.<ref>Garcia DA, Baglin TP, Weitz JI, et al. (2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</ref>

Mholtz at 01:20, 25 December 2016

2016-12-25T01:20:36Z

← Revisión anterior		Revisión del 01:20 25 dic 2016
Línea 1:		Línea 1:
	==Background==		==Background==
	A class of anticoagulant medications. These drugs are used for treating deep vein thrombosis, pulmonary embolism when it is located in the veins, or heart attacks and strokes when located in the arteries. LMWHs cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests. Rather, LMWH therapy is monitored by the anti-factor Xa assay, measuring anti-factor Xa activity.		*A class of anticoagulant medications.
			*Defined as heparin salts having an average molecular weight of less than 8000 Dalton
	~~LMWHs are defined~~ as heparin salts having an average molecular weight of less than 8000 Dalton. LMWHs inhibit the coagulation process through binding to antithrombin which in turn ~~inhibition~~ activated factor X.<ref>Garcia DA, Baglin TP, Weitz JI, et al. (2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</ref>		*LMWHs inhibit the coagulation process through binding to antithrombin which in turn inhibits activated factor X.<ref>Garcia DA, Baglin TP, Weitz JI, et al. (2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</ref>
			*LMWH therapy is monitored by the anti-factor Xa assay (measures anti-factor Xa activity).
			**Cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests.

	==Types==		==Types==
Línea 41:		Línea 43:
	*[[Non ST-Elevation Myocardial Infarction (NSTEMI)]]		*[[Non ST-Elevation Myocardial Infarction (NSTEMI)]]
	*[[ST-segment elevation myocardial infarction (STEMI)]]		*[[ST-segment elevation myocardial infarction (STEMI)]]
			*[[Stroke (main)]]

	==See Also==		==See Also==

Mholtz at 01:18, 25 December 2016

2016-12-25T01:18:02Z

← Revisión anterior		Revisión del 01:18 25 dic 2016
Línea 30:		Línea 30:
	*Less frequent subcutaneous dosing		*Less frequent subcutaneous dosing
	*Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.		*Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.
	*No need for monitoring of the ~~[[APTT]]~~ coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>		*No need for monitoring of the aPTT coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>
	*Possibly a smaller risk of bleeding		*Possibly a smaller risk of bleeding
	*Smaller risk of [[osteoporosis]] in long-term use.		*Smaller risk of osteoporosis in long-term use.
	*Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].		*Smaller risk of [[Heparin-Induced Thrombocytopenia (HIT)\|heparin-induced thrombocytopenia]], a potential side effect of [[Unfractionated heparin\|heparin]].
	*The anticoagulant effects of heparin are typically reversible with [[protamine sulfate]], while protamine's effect on LMWH is limited.		*The anticoagulant effects of heparin are typically reversible with [[Protamine sulfate\|protamine sulfate]], while protamine's effect on LMWH is limited.

	==Indications==		==Indications==
	*[[~~DVT~~]]		*[[Deep venous thrombosis]]
	*[[PE]]		*[[Pulmonary embolism]]
	*[[NSTEMI]]		*[[Non ST-Elevation Myocardial Infarction (NSTEMI)]]
	*[[STEMI]]		*[[ST-segment elevation myocardial infarction (STEMI)]]

	==See Also==		==See Also==
	*[[~~Heparin~~ (~~Unfractionated~~)]]		*[[Coagulopathy (main)]]
	*[[~~Coagulopathy (Main)~~]]		*[[Unfractionated heparin]]

	==References==		==References==

Neil.m.young: Text replacement - "* " to "*"

2016-07-06T17:16:43Z

Text replacement - "* " to "*"

← Revisión anterior		Revisión del 17:16 6 jul 2016
Línea 28:		Línea 28:

	==Clinical Differences from [[Unfractionated heparin]]==		==Clinical Differences from [[Unfractionated heparin]]==
	* Less frequent subcutaneous dosing		*Less frequent subcutaneous dosing
	* Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.		*Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.
	* No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>		*No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>
	* Possibly a smaller risk of bleeding		*Possibly a smaller risk of bleeding
	* Smaller risk of [[osteoporosis]] in long-term use.		*Smaller risk of [[osteoporosis]] in long-term use.
	* Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].		*Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].
	* The anticoagulant effects of heparin are typically reversible with [[protamine sulfate]], while protamine's effect on LMWH is limited.		*The anticoagulant effects of heparin are typically reversible with [[protamine sulfate]], while protamine's effect on LMWH is limited.

	==Indications==		==Indications==

Neil.m.young: Text replacement - "==Source ==" to "==References=="

2016-06-28T01:16:57Z

Text replacement - "==Source ==" to "==References=="

← Revisión anterior		Revisión del 01:16 28 jun 2016
Línea 46:		Línea 46:
	*[[Coagulopathy (Main)]]		*[[Coagulopathy (Main)]]

	==~~Source~~ ==		==References==
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Ostermayer: Text replacement - "Category:Drugs" to "Category:Pharmacology"

2016-03-22T15:53:45Z

Text replacement - "Category:Drugs" to "Category:Pharmacology"

← Revisión anterior		Revisión del 15:53 22 mar 2016
Línea 49:		Línea 49:
	<references/>		<references/>

	[[Category:~~Drugs~~]]		[[Category:Pharmacology]]
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Rossdonaldson1: /* Clinical Differences from Unfractionated heparin */

2015-03-17T14:32:45Z

Clinical Differences from Unfractionated heparin

← Revisión anterior		Revisión del 14:32 17 mar 2015
Línea 31:		Línea 31:
	* Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.		* Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.
	* No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>		* No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>
	* Possibly a smaller risk of [[bleeding~~]].~~		* Possibly a smaller risk of bleeding
	* Smaller risk of [[osteoporosis]] in long-term use.		* Smaller risk of [[osteoporosis]] in long-term use.
	* Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].		* Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].

Rossdonaldson1: /* Differences from unfractionated heparin */

2015-03-17T14:32:29Z

Differences from unfractionated heparin

← Revisión anterior		Revisión del 14:32 17 mar 2015
Línea 27:		Línea 27:
	\|}		\|}

	==Differences from ~~unfractionated heparin==~~		==Clinical Differences from [[Unfractionated heparin]]==
	~~Differences from heparin (i.e. "unfractionated~~ [[heparin]]~~") include:~~		* Less frequent subcutaneous dosing
	* Average molecular weight: heparin is about 15 kDa and LMWH is about 4.5 kDa.<ref>Michael D Randall; Karen E Neil (2004). Disease management. 2nd ed. London: Pharmaceutical Press. 186.</ref>
	* Less frequent subcutaneous dosing ~~than for heparin for postoperative [[prophylaxis]] of venous [[thromboembolism]].~~
	* Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.		* Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high dose heparin.
	* No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>		* No need for monitoring of the [[APTT]] coagulation parameter as required for high dose heparin.<ref>http://chestjournal.chestpubs.org/content/119/1_suppl/64S.full</ref>
Línea 37:		Línea 35:
	* Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].		* Smaller risk of [[heparin-induced thrombocytopenia]], a potential side effect of [[heparin]].
	* The anticoagulant effects of heparin are typically reversible with [[protamine sulfate]], while protamine's effect on LMWH is limited.		* The anticoagulant effects of heparin are typically reversible with [[protamine sulfate]], while protamine's effect on LMWH is limited.
	* Has less of an effect on [[thrombin]] compared to heparin, but about the same effect on Factor Xa.

	==Indications==		==Indications==

Rossdonaldson1: /* Background */

2015-03-17T14:29:19Z

Background

← Revisión anterior		Revisión del 14:29 17 mar 2015
Línea 1:		Línea 1:
	==Background==		==Background==
	A class of anticoagulant medications. These drugs are used for treating deep vein thrombosis, pulmonary embolism when it is located in the veins, or heart attacks and strokes when located in the arteries. LMWHs cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests. Rather, LMWH therapy is monitored by the anti-factor Xa assay, measuring anti-factor Xa activity.		A class of anticoagulant medications. These drugs are used for treating deep vein thrombosis, pulmonary embolism when it is located in the veins, or heart attacks and strokes when located in the arteries. LMWHs cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests. Rather, LMWH therapy is monitored by the anti-factor Xa assay, measuring anti-factor Xa activity.

			LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Dalton. LMWHs inhibit the coagulation process through binding to antithrombin which in turn inhibition activated factor X.<ref>Garcia DA, Baglin TP, Weitz JI, et al. (2012). "Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines"</ref>

	==Types==		==Types==

Rossdonaldson1 at 14:25, 17 March 2015

2015-03-17T14:25:38Z

@@ Línea 42: / Línea 42: @@
 *[[NSTEMI]]
 *[[STEMI]]
 ==See Also==